← Back to Search

Radiation Therapy

Stereotactic Ablative Radiotherapy for Cancer (SABR-COMET Trial)

Phase 2
Waitlist Available
Led By Suresh Senan, MRCPFRCR,PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-1
Controlled primary tumor defined as at least 3 months since original tumor treated definitively, with no progression at primary site
Must not have
Serious medical comorbidities precluding radiotherapy
Prior radiotherapy to a site requiring treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare a new, more precise radiation treatment to chemotherapy and older radiation treatments to see if it improves survival and quality of life.

Who is the study for?
This trial is for adults over 18 with a life expectancy of more than 6 months and confirmed metastatic cancer. They should have had no systemic therapy in the month before radiotherapy, be able to consent, and have an ECOG performance status of 0-1. All cancer sites must be treatable with SABR, which excludes those with certain brain or bone metastases or previous treatments like surgery that can't be followed by SABR.
What is being tested?
The study compares Stereotactic Ablative Radiotherapy (SABR), a precise high-dose radiation treatment given over 1-3 weeks, to conventional chemotherapy and radiotherapy. It aims to see if SABR offers better control of cancer with fewer side effects, thus improving survival rates and quality of life.
What are the potential side effects?
Potential side effects include typical reactions associated with radiation such as skin irritation at the treatment site, fatigue, nausea, potential damage to nearby organs depending on where the tumors are located, but these may be reduced due to SABR's precision.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My original cancer site has been stable for at least 3 months after treatment.
Select...
I have no more than 3 cancer spread spots in any one organ.
Select...
I am not a candidate for surgery to remove my cancer according to my medical team.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have health conditions that prevent me from receiving radiotherapy.
Select...
I have had radiation therapy on the area that now needs treatment.
Select...
My first chemotherapy fully eliminated the cancer that can be measured.
Select...
I have fluid buildup due to cancer in the lining of my lung.
Select...
All my cancer sites cannot be treated.
Select...
I need surgery to relieve pressure in my brain from cancer.
Select...
My MRI shows a tumor near my spinal cord or evidence of spinal cord compression.
Select...
My cancer has spread to the bone in my thigh.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
Group II: Standard armActive Control1 Intervention
Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic ablative radiotherapy
2012
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
680 Previous Clinical Trials
421,363 Total Patients Enrolled
London Regional Cancer Program, CanadaOTHER
10 Previous Clinical Trials
1,179 Total Patients Enrolled
VU University of AmsterdamOTHER
100 Previous Clinical Trials
91,440 Total Patients Enrolled

Media Library

Stereotactic ablative radiotherapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01446744 — Phase 2
Cancer Research Study Groups: Stereotactic arm, Standard arm
Cancer Clinical Trial 2023: Stereotactic ablative radiotherapy Highlights & Side Effects. Trial Name: NCT01446744 — Phase 2
Stereotactic ablative radiotherapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01446744 — Phase 2
~10 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top